We present in vivo sequence-specific RNA base editing via adenosine deaminases acting on RNA (ADAR) enzymes with associated ADAR guide RNAs (adRNAs). To achieve this, we systematically engineered adRNAs to harness ADARs, and comprehensively evaluated the specificity and activity of the toolsets in vitro and in vivo via two mouse models of human disease. We anticipate that this platform will enable tunable and reversible engineering of cellular RNAs for diverse applications.
synthesized adRNAs were both an effective format ( Supplementary  Fig. 4 ). (2) adRNAs bearing long antisense domains, both with and without GluR2 domains, sufficed to recruit exogenously expressed ADARs and, to a degree, endogenous ADARs 12 to enable efficient RNA editing ( Fig. 1b and Supplementary Figs. 2b and 5) . (3) The constructs based on the MS2 adRNAs and corresponding MCP-ADAR1/2 fusions showed robust activity, including across a large panel of endogenous genes chosen along a spectrum of different expression levels ( Fig. 1b and Supplementary Figs. 4a and 5). (4) The use of NES and/or hyperactive deaminase domains in the MCP-ADAR1/2 fusions consistently yielded higher RNA editing yields at the target adenosine, but also led to a higher propensity toward editing at nontargeted adenosines in the flanking sequences ( Fig. 1b and Supplementary Figs. 4a and 6a ). To further validate this, we showed that a similar promiscuity ensued also from deletion of the native NLS domain in ADAR2 (∆1-138) 13 , as well as from its hyperactive mutant ADAR2 (E488Q) ( Supplementary Fig. 6b-d ).
(5) These two toolsets were operationally orthogonal when we used adRNAs with short antisense domains: specifically, we evaluated the editing efficiency of the MCP-ADAR2 deaminase domain fusion with a co-expressed MS2 adRNA or GluR2 adRNA and observed on-target editing only via the former. Conversely, we also confirmed that full-length ADAR2 was recruited by GluR2 adRNA and not the MS2 adRNAs ( Supplementary Fig. 3b ).
Having demonstrated the robust activity of this toolset, we next investigated its specificity profiles via analysis of the transcriptomewide off-target A>G editing effected by this system (Fig. 1c ). To this end, HEK293T cells were transfected with each construct and analyzed by RNA sequencing (RNA-seq). Untransfected cells were included as controls. From each sample, we collected ~40 million uniquely aligned sequencing reads. We then used Fisher's exact test to quantify significant changes in A>G editing yields, relative to untransfected cells, at each reference adenosine site having sufficient read coverage. The number of sites with at least one A>G editing event detected in any of the samples was computed. Of these, the number of sites with statistically significant A>G edits, at a false discovery rate (FDR) of 1% and with fold change of at least 1.1, was found to vary over a wide range, from lowest for the MCP-ADAR2 DD-NLS construct to highest for MCP-ADAR1 DD (E1008Q)-NES ( Supplementary Figs. 7-9 and Supplementary Tables 3 and 4 ). To investigate the distribution of editing yields, we generated violin plots considering the A sites whose editing yields changed significantly in at least one sample ( Fig. 1c ). Taken together, our RNA-seq experiments revealed that transcriptome-wide off-target edits were (1) less prevalent in MCP-ADAR constructs with NLS than in constructs with NES; (2) less prevalent in MCP-ADAR2
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NATuRe MeThoDs constructs than in MCP-ADAR1 constructs; (3) less prevalent in the wild-type MCP-ADAR constructs than in the E>Q hyperactive mutants (Supplementary Fig. 8 and Supplementary Table 4 ); and (4) primarily due to ADAR overexpression. In addition, the use of longantisense-domain adRNAs alone to effect on-target editing resulted in the fewest off-targets ( Supplementary Fig. 9 ).
Following these in vitro studies, we next evaluated this system for in vivo RNA-targeting applications using the adRNA with exogenous ADAR expression construct versions, as these consistently enabled the highest in vitro RNA editing yields. We focused first on the mdx mouse model for Duchenne muscular dystrophy (DMD), which bears an ochre stop site in exon 23 of the dystrophin gene. This choice was additionally motivated by the fact that nonsense mutations in general are responsible for nearly 11% of all gene lesions described as causing inheritable human disease, and close to 20% of diseaseassociated single-base substitutions that affect the coding regions of genes 14 . Thus, validation of an RNA editing strategy here would have broad therapeutic application. Toward this, we first optimized RNA editing of stop codons in vitro ( Supplementary Fig. 10a,b) . Notably, we observed that the addition of a second copy of adRNA significantly improved the targeting efficiencies ( Supplementary  Fig. 10c ), and thus in all our in vivo studies we used a dual-adRNA delivery approach. To test the effectiveness of our system in editing the premature stop codon in mdx dystrophin mRNA, we initially evaluated our constructs in vitro ( Supplementary Fig. 10d ). We next packaged our constructs into adenovirus-associated 8 (AAV8), and injected 2 × 10 12 vector genomes per muscle into the tibialis anterior or gastrocnemius muscle of mdx mice. To further benchmark our approach, we concurrently also targeted mdx mice via CRISPR-Cas9-based excision of exon 23 [15] [16] [17] (Fig. 2a ). Four or eight weeks after the injection, tibialis anterior and gastrocnemius muscles were collected from mdx mice, wild-type mice, and mice treated with adRNA targeting and non-targeting controls and with CRISPR-Cas9. Immunofluorescence staining revealed clear restoration of dystrophin expression via targeted RNA editing ( Fig. 2b and Supplementary Fig. 11a ). In addition, neuronal nitric oxide synthase (nNOS) localization was also restored at the sarcolemma ( Fig. 2b and Supplementary Fig. 11a ). RNA editing yields (TAA>TGG/ TAG/TGA) of up to 3.6% and TAA>TGG of up to 2.4% were observed in treated mice ( Fig. 2c and Supplementary Fig. 10e ). Immunoblots of the treated muscles confirmed the immunofluorescence observations, demonstrating 1-2.5% protein restoration ( Supplementary Fig. 11b ). As a benchmark, muscles injected with vectors bearing CRISPR-Cas9 also expectedly led to restoration of dystrophin expression in a subset of the muscle cells ( Fig. 2b) , with immunoblots of the treated muscles confirming up to 10% protein restoration ( Supplementary Fig. 11c ).
To further confirm the efficacy of this approach, we next evaluated ADAR-mediated RNA editing in an independent mouse model of human disease, the male sparse fur ash (spf ash ) model of ornithine transcarbamylase (OTC) deficiency. This spf ash mouse model harbors a G>A point mutation in the last nucleotide of the fourth exon of the OTC gene, which leads to OTC mRNA deficiency and production of a mutant protein 18 (1, 20, 6) ADAR2 (E488Q) + GluR2 adRNA (1, 20, 6) GluR2 adRNA(2,100,50) ADAR2 + GluR2 adRNA (2, 100, 50) GluR2 adRNA(0,100,50) ADAR2 + GluR2 adRNA(0,100,50) 
NATuRe MeThoDs the use of CRISPR-Cas9 and homologous-recombination-based strategies for robust correction of this mutation in neonatal mice 19 . To test the effectiveness of our system in editing the point mutation in spf ash OTC mRNA ( Fig. 2d ), we initially evaluated our constructs in vitro ( Supplementary Fig. 12a ). We next packaged our constructs into AAV8, which has high liver tropism 19 , and injected 2.5 × 10 12 vector genomes per mouse in 10-12-week-old spf ash mice. Three to four weeks post-injection, we collected liver samples from spf ash 
NATuRe MeThoDs mice, wild-type littermates and spf ash mice treated with the ADAR2 targeting and non-targeting vectors and evaluated corresponding editing efficiency via NGS. Notably, after the delivery of adRNA and ADAR2, we observed 0.8-4.7% edited mRNA among the correctly spliced OTC mRNA, and, notably, adRNA alone resulted in low but significant RNA editing yields ( Fig. 2e and Methods). Moreover, after the delivery of the hyperactive ADAR2 mutant (E488Q), we observed a high edited fraction (4.6-33.8%) in the correctly spliced OTC mRNA ( Fig. 2e and Supplementary Fig. 12b ) and 4.6-8.2% in the OTC pre-mRNA ( Supplementary Fig. 12c ), and confirmed a reduction in the incorrectly spliced product ( Supplementary Fig.  12d ). Immunoblots of the treated liver samples confirmed partial (2.5-5%) restoration of OTC protein ( Supplementary Fig. 12e ).
Taken together, our results establish the utility of RNA-guided ADARs for in vivo RNA editing of point mutations. Moving forward, we note that sequence preferences of the ADAR enzymes, tissue-specific regulators of RNA editing, RNA folding, intrinsic half-life, localization, translation machinery 9 and resident RNAbinding proteins can potentially affect the accessibility and editability of target sites in the RNA, and will be important design parameters to consider for efficacious targeting. For instance, in the mdx model, ADAR-based RNA editing approaches have to compete with nonsense-mediated decay of mutant dystrophin mRNA, and also the requirement for effecting two A>I substitutions in the context of non-ideal flanking nucleotides to eliminate the premature stop codon and potential effects on RNA stability and function. Furthermore, in the spf ash model, the need to target the transient OTC pre-mRNA entails rapid target engagement and editing. Further progress will also require addressing of important limitations of the system such as the off-targets induced by intrinsic enzyme-RNA binding, processivity, promiscuity, stimulation of the interferon response by the delivery modalities per se (such as lipid, nanoparticles or viral vectors) leading in turn to potentially altered endogenous ADAR expression, the potential of adRNAs to induce RNA interference ( Supplementary Fig. 13 ) and also offtarget hybridization of the antisense domain of the adRNA, which could potentially have deleterious effects 20 . In this regard, our studies revealed toxicity in mice systemically injected with the hyperactive ADAR mutants ( Supplementary Fig. 14) . While we hypothesize that off-target RNA editing due to the hyperactive version may be responsible for the observed negative effects on mouse health, additional work needs to be performed to ascertain the underlying mechanisms. These studies will be critical to aid systematic improvement in the specificity and safety of this approach. Another important consideration while considering RNA targeting for gene therapy, especially via the use of non-integrating vectors, is the necessity for periodic readministration of the effector constructs owing to the typically limited half-life of edited mRNAs and effectors. In this regard, compared to CRISPR-based RNA editing approaches, the RNA-guided ADAR strategy is directly relevant to human therapeutics because versions of this toolset solely utilize effector RNAs and human proteins. Additionally, as ADARs are widely expressed-for instance, ADAR1 across most human tissues and ADAR2 in particular in the lung and brain-endogenous recruitment of these via adRNAs bearing long-antisense domains (as demonstrated in Figs. 1b and 2e and Supplementary Figs. 2b and 5 ) presents a very attractive strategy for efficacious RNA editing. We thus anticipate that with progressive improvements, this toolset will have broad implications for diverse basic science and therapeutic applications.
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Methods
Vector design and construction. One or two copies of the GluR2 adRNAs were cloned into an AAV vector containing a human U6 and mouse U6 promoter, along with a CMV promoter driving the expression of GFP or the full-length ADAR2 enzyme [21] [22] [23] or its hyperactive mutant ADAR2 (E488Q) 24 . Similarly, one or two copies of the MS2 adRNAs were cloned into an AAV vector bearing the MCP-ADAR1 or MCP-ADAR2 deaminase domain fusions and their hyperactive mutants. To construct the GFP reporters-GFP-Amber, GFP-Ochre and GFP-Opal-three gene blocks were synthesized, with 'TAG' , 'TAA' and 'TGA' , respectively, replacing the Y39 residue of the wild-type GFP, and were cloned downstream of a CAG promoter. To construct the OTC and DMD reporters, 200-bp fragments of the spf ash OTC and mdx DMD transcript bearing the target adenosine(s) to be edited were cloned downstream of the CAG promoter.
Mammalian cell culture and transfection. All HEK293T cells (ATCC) or HEK293FT cells (Thermo Fisher) were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% antibiotic-antimycotic (Thermo Fisher) in an incubator at 37 °C and 5% CO 2 atmosphere. All in vitro transfection experiments were carried out using the commercial transfection reagent Lipofectamine 2000 (Thermo Fisher). All in vitro RNA editing experiments involving a reporter were carried out in 24-well plates using 400 ng of reporter plasmid and 800 ng of the adRNA + enzyme plasmid. All in vitro RNA editing experiments targeting an endogenous transcript were carried out in 24-well plates using 800 ng of the adRNA/enzyme plasmid. dCas13b-ADAR2DDE488Q-based RNA editing experiments were carried out using 800 ng of the enzyme plasmid (Addgene, no. 103864) and 800 ng of the gRNA plasmid. Cells were transfected at 25-30% confluence and harvested 60 h post-transfection for quantification of editing. Chemically synthesized adRNAs (synthesized by either IDT or Synthego) were transfected using Lipofectamine 3000 (Thermo Fisher) at 20 pmol per well.
Production of AAV vectors. The AAV8 particles were produced using HEK293T cells via the triple-transfection method and purified via an iodixanol gradient. Confluency at transfection was about 80%. Two hours before transfection, Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum was added to the HEK293T cells. Each virus was produced in 5 × 15 cm plates, where each plate was transfected with 7.5 μg of pXR-8, 7.5 μg of recombinant transfer vector and 7.5 μg of pHelper vector using polyethylenimine (PEI) (1 μg μl -1 linear PEI in 1× Dulbecco's phosphate-buffered saline, pH 4.5, using hydrochloric acid) at a PEI:DNA mass ratio of 4:1. The mixture was incubated for 10 min at room temperature and then applied dropwise onto the cell media. The virus was harvested after 72 h and purified using an iodixanol density gradient ultracentrifugation method. The virus was then dialyzed with 1× phosphatebuffered saline (pH 7.2) supplemented with 50 mM sodium chloride and 0.0001% Pluronic F68 (Thermo Fisher) using 50-kDA filters (Millipore), to a final volume of ~1 ml, and quantified by quantitative PCR using primers specific to the ITR region, against a standard (ATCC VR-1616): AAV-ITR-F, 5′-CGGCCTCAGTGAGCGA-3′; AAV-ITR-R, 5′-GGAACCCCTAGTGATGGAGTT-3′.
RNA isolation and next-generation sequencing library preparation. Extraction of RNA from animal tissue was done using the RNeasy Plus Universal Mini Kit (Qiagen), according to the manufacturer's protocol. RNA from cells was extracted using the RNeasy Mini Kit (Qiagen). Complementary DNA (cDNA) was synthesized from 500 ng of RNA using the Protoscript II First Strand cDNA synthesis Kit (NEB). Next-generation sequencing libraries were prepared as follows. Briefly, 1 μl of cDNA prepared as above was amplified by PCR with primers that amplify about 150 bp surrounding the sites of interest using KAPA Hifi HotStart PCR mix (Kapa Biosystems). PCR products were purified (Qiagen PCR purification kit/gel extraction kit) to eliminate by-products. Libraries were constructed with the NEBNext Multiplex Oligos for Illumina kit (NEB). Next, 10 ng of input DNA was amplified with indexing primers. Samples were then pooled and loaded on either an Illumina MiSeq (150 bp single-end run) or HiSeq (100 bp paired-end run). Data analysis was performed using CRISPResso 25 . A minimum of 100,000 reads were analyzed for all in vivo experiments. RNA-seq libraries were prepared from 300 ng of RNA using the NEBNext poly(A) mRNA magnetic isolation module and NEBNext Ultra RNA library prep kit for Illumina. Samples were pooled and loaded on an Illumina HiSeq (100 bp paired-end run).
Quantification of OTC mRNA editing yields in spf ash mice.
The spf ash mouse model has three forms of OTC RNA: pre-mRNA, the correctly spliced mRNA and an incorrectly spliced, elongated mRNA formed owing to the use of a cryptic splice site 48 bp into intron 4 18 . Let the total number of correctly spliced mRNA be X, incorrectly spliced variant be Y and pre-mRNA be Z. Xe, Ye and Ze denote the A>G edited mRNA in the three forms. The mRNA editing yield ideally would be calculated as (Xe + Ye + Ze)/(X + Y + Z). However, because it is not possible to amplify spliced and pre-mRNA variants using the same primers, in Fig. 2e we report the fraction of edited transcripts in the correctly spliced mRNA (Xe/X), which will in turn be translated to produce the OTC protein. In addition, in Supplementary Fig. 12c we also report the fraction of edited transcripts in pre-mRNA (Ze/Z). This fraction, following correct splicing, will contribute to the formation of OTC protein. Finally, incorrectly spliced mRNA results in the production of a protein elongated by 16 amino acids, which is selectively degraded. Supplementary Fig. 12d shows bands corresponding to X and Y.
Animal experiments. All animal procedures were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of the University of California, San Diego. All mice were acquired from Jackson Labs. AAVs were injected into either the gastrocnemius or tibialis anterior muscle of mdx mice (C57BL/10ScSn-Dmd mdx /J) using 2.5 × 10 12 vector genomes per muscle. AAVs were injected into spf ash mice (B6EiC3Sn a/A-Otc spf-ash /J) by retro-orbital injection using 2.5 × 10 12 vector genomes per mouse. Mice that appeared to have a rough hair coat, moved slowly and appeared slightly hunched were termed sick mice and were euthanized.
Immunofluorescence. Harvested gastrocnemius or tibialis anterior muscles were placed in molds containing OCT compound (VWR) and flash-frozen in liquid nitrogen. Sections of 10 μm were cut onto pretreated histological slides. Slides were fixed using 4% paraformaldehyde. Dystrophin and nNOS were detected with rabbit polyclonal antibodies against the C-terminal domain of dystrophin (1:200, Abcam, No. 15277) and the N-terminal domain of nNOS (1:100, Immunostar, No. 24431), respectively, followed by donkey anti-rabbit Alexa Fluor 546 secondary antibody (1:400, Thermo Fisher).
Immunoblots. Muscle biopsies from mdx mice and liver biopsies from spf ash mice were fragmented in RIPA buffer (Sigma) with a proteinase inhibitor cocktail (Roche) and incubated for 1 h on ice with intermittent vortexing. Samples were centrifuged at 15,500g for 30 min at 4 °C, and the supernatant was isolated and quantified with a Pierce Coomassie Plus (Bradford) assay kit (Thermo Fisher). Protein isolate was mixed with 4× Laemmli loading buffer (Bio-Rad) and 2-mercaptoethanol (Bio-Rad) and boiled at 100 °C for 10 min. Total protein (100 μg) from muscle biopsies or 60 μg from liver biopsies was loaded into each well of a 4-15% Mini Protean TGX gel (Bio-Rad) with Tris-glycine-SDS buffer (Bio-Rad) and electrophoresed for 60 min at 100 V. Protein from muscle biopsies was transferred to nitrocellulose membranes overnight at 34 V, while that from liver biopsies was transferred at 65 V for 1 h 30 min in a 1× Tris-glycine transfer buffer containing 10% methanol and 0.1% SDS at 4 °C. The blot was blocked for 1 h in 5% milk-Tris-buffered saline with Tween (TBST). Blots were probed with rabbit anti-dystrophin (1:200, Abcam, no. 15277), rabbit anti-GAPDH (1:4,000, Cell Signaling, no. 2118 S), rabbit anti-OTC (1:800, Abcam, no. 203859) and mouse anti-ADAR2 (1:150, Santa Cruz Biotechnology, no. 73409) overnight at 4 °C in 5% milk-TBST. Blots were washed with TBST and then incubated with anti-rabbit or anti-mouse horseradish-peroxidase-conjugated secondary antibodies (Cell Signaling) for 1 h in 5% milk-TBST. After being washed with TBST, blots were visualized with SuperSignal West Femto Chemiluminescent Substyeild (Thermo Fisher) and radiography.
Statistics and reproducibility.
In vitro experiments. All in vitro experiments were carried out once with a minimum of three independent replicates.
In vivo experiments. For the mdx mouse model, ADAR2 and MCP-ADAR1 (E1008Q) NLS-based experiments were carried out twice. Both rounds of experiments yielded consistent RNA editing efficiencies, dystrophin immunofluorescence and dystrophin restoration as seen by immunoblots. ADAR2 (E488Q)-and CRISPR-Cas9-based experiments were carried out once. For the spf ash mouse model, all experiments were carried out twice, based on the availability of mice. RNA editing efficiencies of the OTC transcript, both spliced and pre-mRNA, were consistent in both rounds of experiments. RT-PCR and immunoblots were carried out on all animals in experimental set 1.
Quantification of RNA A>G editing. RNA-seq read alignment. RNA-seq read pairs with 100 bases per read mate were aligned to the GRCh38 reference genome using STAR aligner version 2.6.0c (ref. 26 ). The genome index was built using primary assembly annotations from GENCODE release 28 (GRCh38.p12). Default parameters were used to run STAR, except for the following relevant settings: readMapNumber = −1, alignSJoverhangMin = 5, alignSJDBoverhangMin = 1, alignEndsType = EndToEnd, outFilterMismatchNmax = 10, outFilterMultimapNmax = 1, outSAMunmapped = 0, outSAMmultNmax = 1. The reads of the resulting uniquely aligned pairs were sorted by genomic coordinates using samtools sort 27 . Duplicated read pairs were marked using samtools markdup and were removed from subsequent analysis. Tallies of total, aligned, duplicated and remaining reads (not pairs) are reported for each sample in Supplementary Table 3 .
Selection of reference sites for quantification of editing yields. The assessment of sites with significant changes in A-to-G editing yields (see below) is sensitive to the number of uniquely aligned reads available for each sample. To minimize potential biases when comparing different samples in terms of significantly edited sites, the uniquely aligned reads for each HEK293T sample were down-sampled using samtools view with option -s, and the down-sampling fractions are reported
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in Supplementary Table 3 . We calculated these fractions by dividing the lowest number of uniquely aligned reads among all samples by the number of uniquely aligned reads available for the sample being down-sampled. Down-sampling was not performed on the reads of the control sample, the first in Supplementary  Table 3 . The down-sampled reads were then processed using samtools mpileup. The output of this tool was parsed to extract the counts of each base found in the aligned reads at each A and T site in the GRCh38 reference genome sequence. Insertions and deletions were ignored. Reference sites with read coverage < 10 were omitted from downstream analysis. The number of remaining reference A and T sites with read coverage ≥ 10 varied by ~15% across the samples listed in Supplementary Table 3 . Without down-sampling, this number was found to vary by ~50%. From the reference A and T sites with read coverage ≥ 10, we selected a final list of total sites (A and T sites) by choosing those sites that were common to all samples and for which at least one G or C was observed at a reference A or T site, respectively, in the aligned reads of at least one sample. The other sites, those not common to all samples or with zero observed editing events in all samples, were discarded.
Assessment of significant changes in A-to-G editing yields.
To uncover significant changes in A-to-G editing yields, we considered several pairs of control and treatment samples. For each pair, the control sample was the first sample listed in Supplementary Table 3 , and the treatment sample was one of the samples shown in Fig. 1 . For each pair of compared samples, and for each reference A site selected as described above, a Fisher exact test was carried out using a 2 × 2 contingency matrix C with entries defined as follows: C 1,1 = count of bases other than G observed in the control sample; C 2,1 = count of G bases observed in the control sample; C 1,2 = count of bases other than G observed in the test sample; and C 2,2 = count of G bases observed in the test sample. A similar contigency matrix was used for each selected reference T site, except that G was replaced with C in the above definitions. The P values calculated for all selected reference sites and for a given comparison of samples were adjusted for multiple testing using the Benjamini-Hochberg method. A and T sites with adjusted P values less than an FDR of 1% and with a fold change of at least 1.1 in editing yield were deemed to have a significant change in A-to-G editing yield on forward and reverse transcripts, respectively. The counts of these sites for each comparison of samples are shown as N sig in Supplementary Fig. 7 , and are reported under the column 'changed sites' in Supplementary Table 4 . The total number of reference sites with a significant change in A-to-G editing yield was computed. The editing yields at these sites were used to construct the distributions shown in Fig. 1c . The on-target A-to-G editing yields shown as blue circles in Fig. 1c and Supplementary Fig. 7 were estimated for each sample as C 2,2 /(C 1,2 + C 2,2 ) using counts observed at the intended target A site in the RAB7A transcript. These values are reported under the column 'editing yield' in Supplementary  Table 4 . The 1-based genomic coordinate of the intended target A site was found to be chr3:128814202 after submission of the following sequence to BLAT after selection of reference assembly h g3 8: A GCGGCAGTATTCTGTACAGTAGACA CAAGAATTATGTACGCCTTTTATCA.
